Literature DB >> 1671402

CD4+ suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-beta.

W J Karpus1, R H Swanborg.   

Abstract

Nylon wool adherent, CD4+ T cells from the spleens of rats that have recovered from experimental autoimmune encephalomyelitis (EAE) inhibit the in vitro production of IFN-gamma, but not IL-2, by effector cells of EAE when cocultured in the presence of myelin basic protein Ag. When anti-transforming growth factor-beta (TGF-beta) antibodies are added to the co-cultures, IFN-gamma production is restored to normal levels. Irrelevant control antibodies have no effect. The same pattern of response was obtained with cells incubated in serum-free medium. In other experiments, purified TGF-beta was added to cultures of effector cells in the presence of antigen. TGF-beta inhibited the production of IFN-gamma by these cells in a dose-dependent manner, but had no apparent inhibitory effect on IL-2 production. Finally, supernatants from cultures containing effector cells and CD4+ suppressor cells plus Ag contained measurable amounts of TGF-beta, whereas supernatants from cultures of effector cells plus Ag contained no measurable amounts of TGF-beta. These results suggest that CD4+ Ts cells of EAE regulate effector cells of EAE through a mechanism that involves the secretion of TGF-beta and that the inhibitory function of this cytokine can be reversed with neutralizing antibodies directed against TGF-beta.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671402

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Regulatory CD8+ T cells fine-tune the myelin basic protein-reactive T cell receptor V beta repertoire during experimental autoimmune encephalomyelitis.

Authors:  H Jiang; S Curran; E Ruiz-Vazquez; B Liang; R Winchester; L Chess
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-24       Impact factor: 11.205

2.  Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.

Authors:  M R Young; M A Wright; M Coogan; M E Young; J Bagash
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  Oral tolerance.

Authors:  W Strober; B Kelsall; T Marth
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

Review 4.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis.

Authors:  G C Suvannavejh; M C Dal Canto; L A Matis; S D Miller
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

6.  Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor.

Authors:  C M Meyers; C J Kelly
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 7.  Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3.

Authors:  Laurence S Harbige
Journal:  Lipids       Date:  2003-04       Impact factor: 1.880

8.  Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice.

Authors:  B S Huneycutt; Z Bi; C J Aoki; C S Reiss
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Shifts in the epitopes of myelin basic protein recognized by Lewis rat T cells before, during, and after the induction of experimental autoimmune encephalomyelitis.

Authors:  F Mor; I R Cohen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  In situ inactivation of infiltrating T cells in the central nervous system with autoimmune encephalomyelitis. The role of astrocytes.

Authors:  Y Matsumoto; H Hanawa; M Tsuchida; T Abo
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.